Flomoxef
(Synonyms: 氟氧头孢) 目录号 : GC36053
Flomoxef 是一种奥沙环类抗生素，对多种革兰氏阳性菌均具有良好的抗菌活性。
Cas No.:99665-00-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Flomoxef is a oxacephem group antibiotic, with excellent activity against various Gram-positive bacteria[1][2].
[1]. Yazawa K, et al. In-vitro activity of flomoxef, a new oxacephem group antibiotic, against Nocardia in comparison with other cephalosporins. J Antimicrob Chemother. 1989 Dec;24(6):921-5. [2]. Simon C, et al. In vitro activity of flomoxef in comparison to other cephalosporins. Infection. 1988 Mar-Apr;16(2):131-4.
| Cas No. | 99665-00-6 | SDF | |
| 别名 | 氟氧头孢 | ||
| Canonical SMILES | O=C(C(N12)=C(CSC3=NN=NN3CCO)CO[C@]2([H])[C@](OC)(NC(CSC(F)F)=O)C1=O)O | ||
| 分子式 | C15H18F2N6O7S2 | 分子量 | 496.47 |
| 溶解度 | Soluble in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.0142 mL | 10.0711 mL | 20.1422 mL |
| 5 mM | 0.4028 mL | 2.0142 mL | 4.0284 mL |
| 10 mM | 0.2014 mL | 1.0071 mL | 2.0142 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Flomoxef and fosfomycin in combination for the treatment of neonatal sepsis in the setting of highly prevalent antimicrobial resistance
J Antimicrob Chemother 2022 Apr 27;77(5):1334-1343.PMID:35170719DOI:10.1093/jac/dkac038.
Background: Neonatal sepsis is a serious bacterial infection of neonates, globally killing up to 680 000 babies annually. It is frequently complicated by antimicrobial resistance, particularly in low- and middle-income country (LMIC) settings with widespread resistance to the WHO's recommended empirical regimen of ampicillin and gentamicin. Objectives: We assessed the utility of Flomoxef and fosfomycin as a potential alternative empirical regimen for neonatal sepsis in these settings. Methods: We studied the combination in a 16-arm dose-ranged hollow-fibre infection model (HFIM) experiment and chequerboard assays. We further assessed the combination using clinically relevant regimens in the HFIM with six Enterobacterales strains with a range of Flomoxef/fosfomycin MICs. Results: Pharmacokinetic/pharmacodynamic modelling of the HFIM experimental output, along with data from chequerboard assays, indicated synergy of this regimen in terms of bacterial killing and prevention of emergence of fosfomycin resistance. Flomoxef monotherapy was sufficient to kill 3/3 strains with Flomoxef MICs ≤0.5 mg/L to sterility. Three of three strains with Flomoxef MICs ≥8 mg/L were not killed by fosfomycin or Flomoxef monotherapy; 2/3 of these were killed with the combination of the two agents. Conclusions: These data suggest that Flomoxef/fosfomycin could be an efficacious and synergistic regimen for the empirical treatment of neonatal sepsis in LMIC settings with prevalent antimicrobial resistance. Our HFIM results warrant further assessment of the Flomoxef/fosfomycin combination in clinical trials.
Flomoxef for neonates: extending options for treatment of neonatal sepsis caused by ESBL-producing Enterobacterales
J Antimicrob Chemother 2022 Feb 23;77(3):711-718.PMID:34969066DOI:10.1093/jac/dkab468.
Background: Neonatal sepsis is a serious and frequently lethal infection, often complicated by antimicrobial resistance (including ESBLs) in low- and middle-income countries (LMICs). Flomoxef is an off-patent oxacephem β-lactam with stability against non-AmpC ESBLs, with potential for utility in these settings. To date, there has been no published Flomoxef neonatal population pharmacokinetic (PopPK) model. Objectives: To summarize the clinical data available for Flomoxef, build a neonatal PopPK model and assess the adequacy of different neonatal Flomoxef regimens. Methods: A systematic literature search returned all available clinical or pharmacokinetic data of Flomoxef use in neonates. Pharmacokinetic data were used to construct a PopPK model, with progressive incorporation of covariates into the final model. Monte Carlo simulations were performed using this final model to simulate drug exposures of different Flomoxef regimens to calculate PTAs. Results: Individual-level clinical and pharmacokinetic data were extracted for 313 and 146 neonates, respectively, with population clinical data extracted for a further 199 neonates. Clinical and microbiological success rates were 89.71% and 82.8%, respectively, with minimal side effects. The final PopPK model incorporated body weight and postnatal age as covariates. PTA analyses predicted that IV regimens of 20 mg/kg q12h, 20 mg/kg q6-8h and 40 mg/kg q6-8h are adequate for neonates aged 0-7, 7-14 and 14-28 days, respectively. Conclusions: To the best of our knowledge, this is the first published neonatal PopPK model for Flomoxef. Given the high treatment success rates, low toxicity rates and off-patent status, this drug has potential for use in the treatment of neonatal sepsis in ESBL-prevalent LMIC settings.
Assessment of Flomoxef combined with amikacin in a hollow-fibre infection model for the treatment of neonatal sepsis in low- and middle-income healthcare settings
J Antimicrob Chemother 2022 Nov 28;77(12):3349-3357.PMID:36177766DOI:10.1093/jac/dkac323.
Background: Annual mortality from neonatal sepsis is an estimated 430 000-680 000 infants globally, most of which occur in low- and middle-income countries (LMICs). The WHO currently recommends a narrow-spectrum β-lactam (e.g. ampicillin) and gentamicin as first-line empirical therapy. However, available epidemiological data demonstrate high rates of resistance to both agents. Alternative empirical regimens are needed. Flomoxef and amikacin are two off-patent antibiotics with potential for use in this setting. Objectives: To assess the pharmacodynamics of Flomoxef and amikacin in combination. Methods: The pharmacodynamic interaction of Flomoxef and amikacin was assessed in chequerboard assays and a 16-arm dose-ranged hollow-fibre infection model (HFIM) experiment. The combination was further assessed in HFIM experiments mimicking neonatal plasma exposures of clinically relevant doses of both drugs against five Enterobacterales isolates with a range of Flomoxef/amikacin MICs. Results: Flomoxef and amikacin in combination were synergistic in bacterial killing in both assays and prevention of emergence of amikacin resistance in the HFIM. In the HFIM assessing neonatal-like drug exposures, the combination killed 3/5 strains to sterility, (including 2/5 that monotherapy with either drug failed to kill) and failed to kill the 2/5 strains with Flomoxef MICs of 32 mg/L. Conclusions: We conclude that the combination of Flomoxef and amikacin is synergistic and is a potentially clinically effective regimen for the empirical treatment of neonatal sepsis in LMIC settings and is therefore suitable for further assessment in a clinical trial.
Antimicrobial resistance surveillance of Flomoxef in China
J Infect Chemother 2015 May;21(5):402-4.PMID:25694055DOI:10.1016/j.jiac.2015.01.008.
The aim of this study was to investigate the susceptibility of Flomoxef against clinical isolates collected from China and understand the trend of antimicrobial resistance. A total of 2955 pathogenic strains isolated from 18 tertiary hospitals in 18 cities of China over the period from July 2011 to June 2012 were studied. And the susceptibility tests were performed using agar dilution method recommended by CLSI in central laboratory. Flomoxef showed good potency against Enterobacteriaceae with susceptibility rate 85%-100%. The susceptibility rates of Flomoxef against Staphylococcus spp. isolates were 63.9%-92.2%; 98.8% of MSSA and 88.2% of MSSE were susceptible to this drug. For other tested bacteria including Moraxella catarrhalis, Haemophilus spp., and Streptococcus spp. (except Viridans group streptococci) Flomoxef showed good potency with susceptibility rate more than 95%. All these results strongly suggest that Flomoxef is a potent antibacterial agent against major pathogens in China.
Intravitreal Flomoxef sodium in rabbits
Ophthalmic Res 1993;25(2):128-36.PMID:8321517DOI:10.1159/000267275.
We studied the intraocular concentration of Flomoxef sodium in nonvitrectomized and vitrectomized eyes of albino rabbits after intravenous administration of 100 mg/kg Flomoxef sodium. The concentration of Flomoxef sodium in the vitreous body was undetectable (< 0.1 micrograms/ml) in nonvitrectomized eyes. Retinal toxicity of Flomoxef sodium was investigated with ophthalmoscopy, electroretinography (ERG) and light microscopy after intravitreal injection of 200, 500, 1,000 and 2,000 micrograms Flomoxef sodium in albino and pigmented rabbits. No ERG changes were induced with 200 micrograms. Other higher doses caused transient ERG changes. After the 200-micrograms injection, the intravitreal concentration decreased exponentially, the half-life being 4.4 h. The antibacterial activity, broad coverage and low intravitreal toxicity of Flomoxef sodium suggest that this compound may be used to treat bacterial endophthalmitis.